Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3846811-B1 | COMBINATION OF APREPITANT, BUPIVACAINE, AND MELOXICAM FOR USE IN THE TREATMENT OF POST-SURGICAL PAIN | HERON THERAPEUTICS INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12115254-B2 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | HERON THERAPEUTICS, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240238197-A1 | METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONIST | HERON THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240139106-A1 | METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONIST | HERON THERAPEUTICS, INC. | 2024-05-02 | — | — | US | disclosed |
| US-11878074-B2 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | HERON THERAPEUTICS, INC. (US) | 2024-01-23 | — | — | US | disclosed |
| US-11744800-B2 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | HERON THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230072781-A1 | METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONIST | HERCULES CAPITAL, INC., AS AGENT | 2023-03-09 | — | — | US | disclosed |
| US-11173118-B2 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof | HERON THERAPEUTICS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210338820-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIEMETIC COMPOUNDS AND POLYORTHOESTER | HERON THERAPEUTICS, INC. | 2021-11-04 | — | — | US | disclosed |
| US-20210173877-A1 | METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONIST | HERCULES CAPITAL, INC., AS AGENT | 2021-06-10 | — | — | US | disclosed |
| US-20040058914-A1 | Combination drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-25 | — | — | US | disclosed |
| US-20040023843-A1 | Preventives/remedies for emotional disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1323429-A1 | PREVENTIVES/REMEDIES FOR EMOTIONAL DISORDERS | Takeda Chemical Industries, Ltd. (JP) | 2003-07-02 | — | — | EP | disclosed |
| EP-0733632-B1 | Cyclic compounds, their production and use as tachykinin receptor antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-06-04 | — | — | EP | disclosed |
| US-6489315-B1 | NOVEL CYCLIC COMPOUNDS HAVING AN EXCELLENT TACHYKININ RECEPTOR ANTAGONISTIC EFFECT, AND A METHOD FOR PRODUCING THEM, FOR TREATING DISORDERS OF INCONTINENCE, ASTHMA, MIGRAINE, IRRITABLE BOWEL SYNDROME, PAIN, COUGH OR EMESIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020132817-A1 | Heterocyclic compounds, their production and use | NATSUGARI HIDEAKI (JP) | 2002-09-19 | — | — | US | disclosed |
| EP-1184036-A2 | Heterocyclic compounds, their production and use as tachykinin receptor antagonists | Takeda Chemical Industries, Ltd. (JP) | 2002-03-06 | — | — | EP | disclosed |
| EP-1145714-A1 | DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2001-10-17 | — | — | EP | disclosed |
| US-6147071-A | TACHYKININ RECEPTOR ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-11-14 | — | — | US | disclosed |
| EP-0733632-A1 | Cyclic compounds, their production and use as tachykinin receptor antagonists | Takeda Chemical Industries, Ltd. (JP) | 1996-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338820-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIEMETIC COMPOUNDS AND POLYORTHOESTER | TACR1, NPSR1, TAC3 | TACR1 1/4885PDE4A 2212/4885 |
| US-20040023843-A1 | Preventives/remedies for emotional disorders | MTNR1A, KISS1R, MTNR1B | TACR1 12/4885PDE4A 419/4885 |
| US-20020132817-A1 | Heterocyclic compounds, their production and use | CRH, CRHR1, CRHR2 | TACR1 97/4885PDE4A 3673/4885 |
| US-20040058914-A1 | Combination drugs | CHRNA1, CHRNA2, CHRM2 | TACR1 39/4885PDE4A 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.